Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 6, 2010, Pages 213-237

  La Regina, Giuseppe ^a   Coluccia, Antonio ^a   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3,5 DIETHYL 1 (2 HYDROXYETHYL) 4 PYRAZOLYLOXY] 1,3 BENZENEDINITRILE; ABACAVIR; AMPRENAVIR; ATAZANAVIR; BIRL 355BS; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; IDX 899; INDINAVIR; LAMIVUDINE; MARAVIROC; MK 4965; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PTIVUS; RALTEGRAVIR; RDEA 806; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TALVIRALINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BINDING SITE; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG CONFORMATION; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BINDING SITES; CELL LINE; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDOLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NITRILES; PHOSPHINIC ACIDS; PYRAZOLES; PYRIDAZINES; PYRIDINES; PYRIMIDINES; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77956900680     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1607     Document Type: Review

References (142)

1. UNAIDS. Status of the global HIV epidemic. Report on the global AIDS epidemic. Geneva: UNAIDS 2008; pp. 29-62.
2. Scherer E, Douek D, McMichael A. 25 Years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines. Clin Exp Immunol 2008; 154:6-14.
3. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995; 38:2491-2517.
4. De Clercq E. Highlights in the development of new antiviral agents. Mini Rev Med Chem 2002; 2:163-175.
5. Williams IG. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract 2003; 57:890-897.
6. Oversteegen L, Shah M, Rovini H. HIV combination products. Nat Rev Drug Discov 2007; 6:951-952.
7. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′- deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82:7096-7100.
8. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6:1001-1018.
9. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11:1805-1843.
10. Orkin C, Stebbing J, Nelson M, et al. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy. J Antimicrob Chemother 2005; 55:246-251.
11. Li X, Margolick JB, Connover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2005; 38:320-328. (Pubitemid 40333499)
12. Vandamme A-M, Van Vaerenbergh K, De Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 1998; 9:187-203.
13. Cheng YC, Dutschman GE, Bastow KF, Sarngadharan MG, Ting RY. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 1987; 262:2187-2189.
14. Jacobo-Molina A, Clark AD, Jr., Williams RL, et al. Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract X-rays to 3.5-Å resolution. Proc Natl Acad Sci U S A 1991; 88:10895-10899.
15. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783-1790.
16. Jacobo-Molina A, Ding J, Nanni RG, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90:6320-6324.
17. Rodgers DW, Gamblin SJ, Harris BA, et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1995; 92:1222-1226.
18. Cohen KA, Hopkins J, Ingraham RH, et al. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 1991; 266:14670-14674.
19. Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistant mutations in the three dimensional structure of HIV-1 reverse trancriptase. J Mol Biol 1994; 243:369-387.
20. Baba M, Tanaka H, De Clercq E, et al. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 1989; 165:1375-1381.
21. Miyasaka T, Tanaka H, Baba M, et al. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J Med Chem 1989; 32:2507-2509.
22. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990; 343:470-474. (Pubitemid 120028562)
23. Debyser Z, Pauwels R, Andries K, et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4] benzodiazepin-2(1H)-one and -thione derivatives. Proc Natl Acad Sci U S A 1991; 88:1451-1455.
24. Kukla MJ, Breslin HJ, Pauwels R, et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)one (TIBO) derivatives. J Med Chem 1991; 34:746-751.
25. Kukla MJ, Breslin HJ, Diamond CJ, et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin- 2(1H)one (TIBO) derivatives. 2. J Med Chem 1991; 34:3187-3197.
26. Breslin HJ, Kukla MJ, Ludovici DW, et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin- 2(1H)one (TIBO) derivatives. 3. J Med Chem 1995; 38:771-793.
27. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250:1411-1413.
28. Hargrave KD, Proudfoot JR, Grozinger KG, et al. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Triciclyc pyridobenzo- and dipiridodiazepinones. J Med Chem 1991; 34:2231-2241.
29. Klunder JM, Hargrave KD, West M, et al. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridoxazepinones and dibenzoxazepinones. J Med Chem 1992; 35:1887-1897.
30. Proudfoot JR, Patel UR, Kapadia SR, Hargrave KD. Novel non-nucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 3. Dipyrido[2,3-b:2′,3′-c]diazepinones. J Med Chem 1995; 38:1406-1410.
31. Romero DL, Morge RA, Genin MJ, et al. Bis(heteroaryl) piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogs and the identification of 1-[(5-methanesulfonamido- 1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino] pyridinyl] piperazinemonomethanesulfonate (U-90152S), a second-generation clinical candidate. J Med Chem 1993; 36:1505-1508.
32. Romero DL, Morge RA, Biles C, et al. Discovery, synthesis and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside reverse transcriptase inhibitors. J Med Chem 1994; 37:999-1014.
33. Romero DL, Olmsted RA, Poel TJ, et al. Targeting delarvidine/atervidine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl) piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. J Med Chem 1996; 39:3769-3789.
34. Genin MJ, Poel TJ, Yagi Y, et al. Syntehsis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationship and increased metabolic stability of novel substituted pyridine analogs. J Med Chem 1996; 39:5267-5275.
35. Freimuth WW. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Biol 1996; 394:279-289.
36. Goldman ME, Nunberg JH, O'Brien JA, et al. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A 1991; 88:6863-6867.
37. Corbett JW, Kresge KJ, Pan S, et al. Trifluoromethyl-containing 3-alkoxymethyl and 3-aryloxymethyl-2-pyridones are potent inhibitors of HIV-1 non-nnucleoside reverse transcriptase. Bioorg Med Chem Lett 2001; 11:309-312.
38. Artico M. Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs fro clinical trials. Farmaco 1996; 51:305-331.
39. Pedersen OS, Pedersen EB. Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antivir Chem Chemother 1999; 10:285-314.
40. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future. Chem Biodivers 2004; 1:44-64.
41. Hajós G, Riedl Z, Molnár J, Szabó D. Nonnucleoside reverse transcriptase inhibitors. Drugs Fut 2000; 25:47-62.
42. Campiani G, Ramunno A, Maga G, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002; 8:615-657.
43. De Clercq E. Antivirals: current state of art. Future Virol 2008; 3:393-405.
44. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicr Ag 2009; 33:307-320.
45. Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42:1340-1345.
46. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999; 9:1593-1598.
47. Taylor DL, Ahmed PS, Chambers P, et al. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Antivir Chem Chemother 1999; 10:79-86.
48. Tucker TJ, Lyle TA, Wiscount CM, et al. Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 1994; 37:2437-2444.
49. Young SD, Brichter SF, Tran LO, et al. L-743,726 (DMP-266): a novel nonnucleoside inhibitor of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39:2602-2605.
50. Graul A, Rabasseda X, Castaner J. Efavirenz. Drugs Fut 1998; 23:133-141.
51. Corbett JW, Ko SS, Rodgers JD, et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem 2000; 43:2019-2030.
52. Cocuzza AJ, Chidester DR, Cordova BC, et al. Synthesis and evaluation of efavirenz (SustivaTM) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain. Bioorg Med Chem Lett 2001; 11:1177-1179.
53. Corbett JW, Ko SS, Rodgers JD, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:2893-2897.
54. Corbett JW, Rodgers JD. Discovery of second generation quinazoline non-nucleoside reverse transcriptase inhibitors. Prog Med Chem 2002; 40:63-105.
55. Bell FW, Cantrell AS, Hogberg M, et al. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J Med Chem 1995; 38:4929-4936.
56. Cantrell AS, Engelhardt P, Hogberg M, et al. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J Med Chem 1996; 39:4261-4274.
57. Hogberg M, Sahlberg C, Engelhardt P, et al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J Med Chem 1999; 42:4150-4160.
58. Balzarini J, Brouwer WG, Dao DC, Osika EM, De Clercq E. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother 1996; 40:1454-1466.
59. Balzarini J, Pelemans H, Aquaro S, et al. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 1996; 50:394-401.
60. Botta M, Artico M, Massa S, et al. Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives. Eur J Med Chem 1992; 27:251-257.
61. Danel K, Nielsen C, Pedersen EB. Anti-HIV active naphthyl analogues of HEPT and DABO. Acta Chem Scand 1997; 51 Suppl 3:426-430.
62. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L, Uckun FM. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1998; 42:3225-3233.
63. Mai A, Artico M, Sbardella G, et al. 5-Alkyl-2-(alkylthio)-6-(2,6- dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyloxopyrimidine derivatives. J Med Chem 1999; 42:619-627.
64. Mai A, Artico M, Sbardella G, et al. Dihydro(alkylthio) (naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J Med Chem 1997; 40:1447-1454.
65. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM. 5-Alkyl-2-[(methylthiomethyl) thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioorg Med Chem Lett 1998; 8:1461-1466. (Pubitemid 28281405)
66. Radi M, Maga G, Alongi M, et al. Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. J Med Chem 2009; 52:840-851.
67. Tucker TJ, Sisko JT, Tynebor RM, et al. Discovery of 3-{5-[(6- amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy} -5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J Med Chem 2008; 51:6503-6511.
68. De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005; 48:1689-1696.
69. Janssen PAJ, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine). J Med Chem 2005; 48:1901-1909.
70. Artico M, Silvestri R, Stefancich G, et al. Synthesis of pyrryl aryl sulfones targeted at the HIV-1 reverse transcriptase. Arch Pharm (Weinheim) 1995; 328:223-229.
71. Artico M, Silvestri R, Massa S, et al. 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. J Med Chem 1996; 39:522-530.
72. Artico M, Silvestri R, Pagnozzi E, et al. Structure-based design, synthesis and biological evaluation of novel pyrrolyl aryl sulfones (PASs), HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. J Med Chem 2000; 43:1886-1891. (Pubitemid 30305021)
73. Silvestri R, De Martino G, La Regina G, et al. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J Med Chem 2003; 46:2482-2493.
74. Silvestri R, Artico M, De Martino G, et al. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild-type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J Med Chem 2004; 47:3892-3896.
75. Ragno R, Artico M, De Martino G, et al. Docking and 3-D QSAR studies on indolyl aryl sulfones (IASs). Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl) carboxyamide and N-(2-hydroxyethyl)carboxyhydrazide derivatives. J Med Chem 2005; 48:213-223.
76. Silvestri R, Artico M. Indolyl aryl sulfones (IASs): Development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants. Curr Pharm Des 2005; 11:3779-3806.
77. De Martino G, La Regina G, Ragno R, et al. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. Antivir Chem Chemother 2006; 57:59-77.
78. Ragno R, Coluccia A, La Regina G, et al. Design, molecular modeling, synthesis and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. J Med Chem 2006; 49:3172-3184.
79. La Regina G, Coluccia A, Piscitelli F, et al. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity. J Med Chem 2007; 50:5034-5038.
80. Piscitelli F, Coluccia A, Brancale A, et al. Indolylarylsulfones bearing natural and unnatural aminoacids. Discovery of potent inhibitors of both HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase, and Coxsackie B4 virus. J Med Chem 2009; 52:1922-1934.
81. King RW, Klabe RM, Reid CD, Erickson-Viitanen SK. Potency of non nucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother 2002; 46:1640-1646.
82. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the clinical management of AIDS/HIV infection in adult people. US Department of Health and Human services. 1 December 2009. (Updated 01 December 2009. Accessed 07 February 2010.) Available from http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf
83. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidivudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidivudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-1873.
84. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolim. Prog Lipid Res 2003; 42:81-92.
85. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolated from patients failing non-nucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75:4999-5008.
86. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448.
87. Abdel-Malak M, Gallati C, Mousa SA. The rise of second-generation non-nucleoside reverse transcriptase inhibitor: etravirine, rilpivirine, UK-453061 and RDEA-806. Drug Fut 2008; 33:691-699.
88. AIDS InfoNet. Non-nucleoside reverse transcriptase inhibitors in development. Fact sheet number 430. (Updated 23 November 2009. Accessed 07 February 2010.) Available from http://www.aidsinfonet.org/categories/view/430
89. Deeks ED, Keating GM. Etravirine. Drugs 2008; 68:2357-2372.
90. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
91. Hang JQ, Li Y, Yang Y, et al. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun 2007; 352:341-350.
92. Figueiredo A, Moore KL, Mak J, et al. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 gag-pol. PLoS Pathog 2006; 2:e119.
93. Das K, Clark AD, Jr., Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47:2550-2560.
94. Pauwels R, Andries K, Debyser Z, et al. New tetrahydroimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob Agents Chemother 1994; 38:2863-2870.
95. Ding J, Das K, Tantillo C, et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor R-APA R 95845 at 2.8 Å resolution. Structure 1995; 3:365-379.
96. Ding J, Das K, Moereels H, et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 1995; 2:407-415.
97. Das K, Ding J, Hsiou Y, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996; 264:1085-1100.
98. Schäfer W, Friebe W-G, Leinert H, et al. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J Med Chem 1993; 36:726-732.
99. Ludovici DW, Kukla MJ, Grous PG, et al. Evolution of anti-HIV drug candidates. Part 1: from α-anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU). Bioorg Med Chem Lett 2001; 11:2225-2228.
100. Ludovici DW, Kavash RW, Kukla MJ, et al. Evolution of anti-HIV drug candidates part 2: diaryltriazine (DATA) analogues. Bioorg Med Chem Lett 2001; 11:2229-2234.
101. Pelemans H, Esnouf RM, Jonckheere H, De Clercq E, Balzarini J. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J Biol Chem 1998; 273:34234-34239.
102. Pelemans H, Esnouf R, De Clercq E, Balzarini J. Mutational analysis of Trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol Pharmacol 2000; 57:954-960.
103. Lewis PJ, de Jonge M, Daeyaert F, et al. On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling. J Comput Aided Mol Des 2003; 17:129-134.
104. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Am Chem Soc 2003; 125:6016-6017.
105. Udier-Blagovic M, Watkins EK, Tirado-Rives J, Jorgensen WL. Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. Bioorg Med Chem Lett 2003; 13:3337-3340.
106. Brunger AT, Adams PD, Rice LM. Recent developments for the efficient crystallographic refinement of macromolecular structures. Curr Opin Struct Biol 1998; 8:606-611.
107. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Am Chem Soc 2003; 125:6016-6017.
108. Ren J, Nichols C, Bird LE, et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 2000; 275:14316-14320.
109. Rizzo RC, Wang D-P, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles. J Am Chem Soc 2000; 122:12898-12900.
110. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
111. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125, a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17:F49-F54.
112. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of nonnucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005; 88:209-231.
113. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48:1901-1909.
114. Clive D, Caspary W, Kirby P, et al. Guide for performing the mouse lymphoma assay for mammalian cell mutagenicity. Mutat Res 1987; 189:143-156.
115. Smet F, D'Aubioul J, van Gerven W, Xhonneux R, Reneman RS. A chronically implantable catheter-tip micromanometer (JSI 0400) that can be calibrated after implantation. Cardiov Res 1979; 13:601-605.
116. Wolford ST, Schroer RA, Gohs FX, et al. Reference range database for serum chemistry and hematology values in laboratory animals. J Toxicol Environ Health 1986; 18:161-188.
117. Pauwels R. Aspects of successful drug discovery and development. Antiviral Res 2006; 71:77-89.
118. Das K, Bauman JD, Clark AD, Jr., et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008; 105:1466-1471.
119. Fang C, Barman JD, Das K, Rumorino A, Arnold E, Hochstrasser RM. Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 2008; 105:1472-1477.
120. Van Herrewege Y, Vanham G, Michiels J, et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. J Antimicrob Chemother 2004; 48:3684-3689.
121. Mordant C, Schmitt B, Pasquier E, et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem 2007; 42:567-579.
122. Girardet J-L, Koh Y-H, La Rosa M, et al. The discovery of RDEA806, a potent new HIV NNRTI in phase 1 clinical trials. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract 3285.
123. Hamtake R, Zhang Z, Xu W, Bellows D, Raney A, Giradet JL. RDEA806, a potent, new HIV NNRTI with a high genetic barrier to resistance and a broad spectrum of activity. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Poster 300.
124. Moyle G, Boffito M, Shen Z, et al. RDEA806, a novel HIV non-nucleoside reverse transcriptase inhbitor, shows positive outcome in treatment of naive HIV patients. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 25-28 October 2008, Washington, DC, USA. (Accessed 5 October 2009.) Available from http://www.ardeabio/com/Docs/icaac-rdea201-presentations- FINAL.pdf
125. Corbau R, Allan G, Burt C, et al. UK-453,061: a non-nucleoside reverse transcriptase inhibitor for the treatment of drug-resistant HIV infections. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract 2751.
126. Bonneau P, Doyon L, Duan J, et al. Characterization of a novel series of NNRTIs with broad antiviral potency against NNRTI-resistant HIV. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Poster 530.
127. Bonneau P, Robinson PA, Duan J, et al. Antiviral characterizazion and human experience with BIRL 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti-HIV-1 profile. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Poster 558.
128. Busacca CA, Cerreta M, Dong Y, et al. Development of a pilot-plant process for a nevirapine analogue HIV NNRT inhibitor. Org Process Res Dev 2008; 12:603-613.
129. Huang F, Koenen-Bergmann M, MacGregor TR, Ring A, Hattox S, Robinson P. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2008; 52:4300-4307.
130. Huang F, Drda K, MacGregor TR, et al. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir. Antimicrob Agents Chemother 2009; 53:95-103.
131. Coulombe R, Fink D, Landry S, et al. Crystallographic study with BILR 355 BS, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract WePp0105.
132. Jakubik J, Seifer M, Gray L, et al. IDX12899 anti-HIV-1 activity and resistance profile is superior to efavirenz. Antivir Ther 2007; 12 Suppl 1:S32.
133. Storer R, Alexandre F-R, Dousson C, et al, inventors; Idenix Pharmaceuticals, Inc. assignee. Enatiomerically pure phosphoindoles as HIV inhibitors. United States patent WO2008/042240. 10 April 2008.
134. Ragno R, Coluccia A, La Regina G, Silvestri R. Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies. Exp Opin Drug Disc 2007; 2:87-114.
135. Ragno R, Mai A, Sbardella G, et al. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3, 4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J Med Chem 2004; 47:928-934.
136. Mayers D, Murphy R, Zala C, et al. IDX899: A novel once-a-day second generation NNRTI for the treatment of HIV/AIDS. HIV DART. 9-12 December 2008, Rio Grande, Puerto Rico. Abstract 43.
137. Tucker TJ, Saggar S, Sisko JT, et al. The design and synthesis of diaryl ether second generation NNRTIs with enhanced potency versus key clinical mutations. Bioorg Med Chem Lett 2008; 18:2959-2966.
138. Tucker TJ, Sisko JT, Tynebor RM, et al. Discovery of 3-{5-[(6-amino-1H- pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J Med Chem 2008; 51:6503-6511.
139. Pauwels R, Andries K, Debyser Z, et al. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:1711-1715.
140. Kleim J-P, Bender R, Kirsch R, et al. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. J Antimicrob Chemother 1995; 39:2253-2257.
141. Hsiou Y, Das K, Ding J, et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 1998; 284:313-323.
142. Hsiou Y, Ding J, Das K, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001; 309:437-445.